Movement Alert|10x Genomics, Inc. Pre-Market Rise 4.71%, raised full-year revenue outlook keeps earnings-driven trading active

Market Focus11-11

On November 11, 10x Genomics, Inc. rose 4.71% in Pre-Market Trading, trading at $66.94 per share, with turnover of $146.6 thousand.

The move followed continued market focus on the company’s recent quarterly results, which beat expectations on both earnings and revenue and included a higher full-year revenue outlook.

In its latest quarterly report, 10x Genomics, Inc. posted a Q3 loss of $0.15 per share, better than expected losses of about $0.25 to $0.27, while revenue of $150.667 million exceeded expectations near $147.9 million to $148.0 million. The company also raised full-year revenue guidance to $625 million-$635 million from $610 million-$630 million, above the consensus estimate of $620.8 million. Recent trading has remained volatile, as the improved operating trend and guidance increase have been offset at times by post-earnings analyst target cuts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment